Brahms gets FDA approval for sepsis test:
This article was originally published in Clinica
German diagnostic company Brahms has received clearance to sell in the US its inflammatory response marker for sepsis, Procalcitonin (PCT). The Berlin-based company said PCT is designed to aid in the risk assessment of critically ill patients, on their first day of ICU admission, for progression to severe sepsis and septic shock. The product is already available in Europe.
You may also be interested in...
Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.